{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:31:43Z","timestamp":1790775103849,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006678","name":"Association Fran\u00e7aise pour l'Etude du Foie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","award":["ALPINE NIHR 155210"],"award-info":[{"award-number":["ALPINE NIHR 155210"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jhepr.2024.101227","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:47:29Z","timestamp":1728506849000},"page":"101227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Hepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-3160","authenticated-orcid":false,"given":"Laura","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-2921","authenticated-orcid":false,"given":"Alexander","family":"Hinkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-0514","authenticated-orcid":false,"given":"Vincent","family":"Haghnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-6836","authenticated-orcid":false,"given":"Rebecca","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-8670","authenticated-orcid":false,"given":"Richard","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-0749","authenticated-orcid":false,"given":"Ian A.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhepr.2024.101227_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101227_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib3","article-title":"Primary liver cancer in the UK: incidence, incidence-based mortality, and survival by subtype, sex, and nation","volume":"3","author":"Burton","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"10.1016\/j.jhepr.2024.101227_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101227_bib7","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101227_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101227_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204412","article-title":"Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis","volume":"13","author":"Ioannou","year":"2018","journal-title":"PloS one"},{"issue":"13","key":"10.1016\/j.jhepr.2024.101227_bib12","article-title":"Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study","volume":"10","author":"Haq","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101227_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101227_bib14","article-title":"Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease","author":"Colli","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101227_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin translational Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/hep.29874","article-title":"Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance","volume":"68","author":"Fung","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101227_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101227_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2024.101227_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9996358","article-title":"Reporting and performance of hepatocellular carcinoma risk prediction models: based on TRIPOD statement and meta-analysis","volume":"2021","author":"Yang","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101227_bib20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2014.01.045","article-title":"A\u00a0new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis","volume":"146","author":"El-Serag","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101227_bib21","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.28702","article-title":"Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)","volume":"64","author":"Ganne-Carrie","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101227_bib22","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032844","article-title":"Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews","volume":"7","author":"Geersing","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jhepr.2024.101227_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.jhepr.2024.101227_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101227_bib27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41416-022-01851-1","article-title":"Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify","volume":"127","author":"Johnson","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib28","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41598-022-05196-w","article-title":"A\u00a0scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis","volume":"12","author":"Lee","year":"2022","journal-title":"Scientific Rep"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/lci2.47","article-title":"Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol-related cirrhosis patients","volume":"3","author":"Liu","year":"2022","journal-title":"Liver Cancer Int"},{"issue":"18","key":"10.1016\/j.jhepr.2024.101227_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184567","article-title":"Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101227_bib31","article-title":"External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population","volume":"3","author":"Astrom","year":"2021","journal-title":"JHEP Rep : innovation Hepatol"},{"key":"10.1016\/j.jhepr.2024.101227_bib32","first-page":"142","article-title":"P081YI: validation of the aMAP risk score for the development of hepatocellular cancer in patients with cirrhosis in Glasgow","author":"Curran","year":"2021","journal-title":"Digital Liver Cancer Summit"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101227_bib33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/MEG.0000000000001685","article-title":"External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients","volume":"32","author":"Demirtas","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101227_bib34","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101227_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12957-019-1619-3","article-title":"Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study","volume":"17","author":"Zhang","year":"2019","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00535-016-1228-7","article-title":"Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases","volume":"52","author":"Aoki","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"issue":"22","key":"10.1016\/j.jhepr.2024.101227_bib38","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/cncr.28832","article-title":"Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model","volume":"120","author":"Flemming","year":"2014","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101227_bib39","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/ajg.2013.332","article-title":"Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma","volume":"108","author":"Singal","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101227_bib40","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","author":"Sharma","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10219","key":"10.1016\/j.jhepr.2024.101227_bib41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(19)32908-3","article-title":"Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK","volume":"395","author":"Williams","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101227_bib42","article-title":"Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection","volume":"3","author":"Innes","year":"2021","journal-title":"JHEP Rep : innovation Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101227_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001221","article-title":"Reporting and methods in clinical prediction research: a systematic review","volume":"9","author":"Bouwmeester","year":"2012","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib44","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101227_bib45","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.14309\/ajg.0000000000001879","article-title":"Comparing predicted probability of hepatocellular carcinoma in patients with cirrhosis with the general population: an opportunity to improve risk communication?","volume":"117","author":"Innes","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101227_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27598","article-title":"The clinical course of cirrhosis: the importance of multistate models and competing risks analysis","volume":"62","author":"Jepsen","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101227_bib47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101227_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.gastha.2021.11.008","article-title":"Competing risk bias in prognostic models predicting hepatocellular carcinoma occurrence: impact on clinical decision-making","volume":"1","author":"Innes","year":"2022","journal-title":"Gastro Hep Adv"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101227_bib50","first-page":"694","article-title":"The natural history of advanced chronic liver disease defined by transient elastography","volume":"21","author":"Shearer","year":"2023"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T15:33:25Z","timestamp":1740324805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2589555924002313"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101227","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101227"}}